#Reyataz

Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

The company is losing its exclusive rights to two HIV drugs: Reyataz and Sustiva.

This is according to a large study of U.S. veterans.

The two-drug regimen can cure the virus in as little as eight weeks.

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Combo treatment with fine-particle formulations of Reyataz and Norvir, plus an immune-dampener drug, greatly reduced HIV levels in mice.

A two-drug regimen of Norvir (ritonavir)Ã¢€“boosted Reyataz (atazanavir) and Epivir (lamivudine) treats HIV as well or better tha...

Research of Bristol-Myers Squibb’s BMS-955176, an HIV maturation inhibitor, has shown the antiretroviral is potent and well-tolerated.

An updated version of Viread (tenofovir) offers slightly better viral suppression and improves indicators of kidney and bone health...

Bristol-Myers Squibb’s investigational next-generation maturation inhibitor BMS-955176 demonstrated good activity against HIV when paired...

The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.

Various HIV antiretrovirals are linked to a raised risk of cardiovascular problems, although the overall risk of such an outcome is still low.

A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...

People with HIV who start treatment with Truvada post similar fat gains whether they pair the tablet with Isentress or protease inhibitors.